Wednesday, 11 July 2012

Acasti Signs Worldwide Distribution Agreement


Acasti Pharma
TSX V: APO
Shares Outstanding: 71.0 million
Fully Diluted: 80.1 million
-------------------------------
 


Florida-based XYMOGEN announced today that it has signed an exclusive partnership with Acasti Pharma, for the worldwide distribution of LipiChol540™, a physician-prescribed medical food to manage omega-3 phospholipid deficiency.

According to the release, LipiChol540™ is the only medical krill oil product in the world. It is pharmaceutically formulated to provide a stronger dosage and lower pill burden, compared to popular fish oil supplements, without the typical unpleasant taste or burping side effects.

We’ve posed additional questions to Acasti management for clarification on the scope of the agreement and expectations based on the news that was released by XYMOGEN.

About XYMOGEN

XYMOGEN, a family owned health sciences company headquartered in Orlando, Fla., has been providing high-quality dietary supplements to licensed healthcare practitioners for more than a quarter century. The nutraceutical company has introduced numerous innovations to the functional medicine community, and its Medical Board of Advisors consists of clinical practitioners who represent a broad range of specialties. XYMOGEN’s unprecedented growth continues with a new, state-of-the-art, 136,000 square foot manufacturing facility and laboratory, and a strategic expansion into Canada and Australia, two of the largest international markets. XYMOGEN’s strength as a company was reinforced in 2007, 2008, 2010, and 2011, when it was recognized by Inc. magazine as one of the 5000 fastest-growing private companies in America.

To read the full news release, please click here